Strategies for Delivering Smarter Pharmacy Benefits

Why It Matters

The shift threatens entrenched PBM profit models and offers employers a lever to lower prescription costs while preserving insurance benefits, directly impacting employee health spending.

Key Takeaways

• GoodRx revealed insurance isn’t always cheapest, sparking PBM scrutiny.
• Direct-to-consumer models like Cost Plus Drugs cut PBM middlemen.
• Employers can demand full rebate and fee disclosure from PBMs.
• Brokers can redesign benefits to combine low cost with coverage credit.
• 2020 saw 6.3 billion prescriptions, about 19 per American, raising costs.

Pulse Analysis

The pharmacy‑benefit landscape is at a crossroads. Since the 1960s, PBMs have justified their role by negotiating discounts and managing formularies, yet their opaque pricing structures—especially spread pricing—have inflated out‑of‑pocket costs for patients. The rise of price‑comparison apps such as GoodRx has democratized data, revealing that cash prices at grocery or independent pharmacies often undercut insurer‑mediated rates. This transparency shock has forced retailers like Walmart to launch flat‑fee generic programs, challenging the PBM monopoly on cost control.

Simultaneously, direct‑to‑consumer (DTC) channels are reshaping drug distribution. Companies like Cost Plus Drugs and manufacturer‑led services such as Lilly Direct sell medications at transparent, lower prices—Zepbound, for example, can be sourced for roughly $400 per month versus the $1,100 typical PBM‑managed cost. While traditional PBM pathways may return rebates to insurers, those savings rarely reach the patient at the point of sale. Employers therefore face a dilemma: accept higher drug prices that count toward deductibles or opt for cheaper DTC options that bypass insurance credits. The choice influences overall health‑plan spend and employee satisfaction.

For brokers and benefits advisers, the imperative is clear: champion full disclosure of administrative fees, rebates, and spread‑pricing practices, and construct hybrid benefit designs that marry low‑cost DTC options with the protective umbrella of insurance. By leveraging technology, negotiating transparent contracts, and educating members on price‑shopping tools, the industry can reduce unnecessary profit margins and improve health outcomes. The evolution may not eliminate PBMs, but it will compel them to adapt to a market demanding clarity, value, and patient‑first solutions.